Date | Interest Coverage Ratio | Debt to Equity Ratio | Interest Expense To Sales | Inventory Turnover Ratio |
---|
CEO | Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D. |
IPO Date | March 8, 2004 |
Location | Japan |
Headquarters | St. Luke’s Tower |
Employees | 1,451 |
Sector | Health Care |
Industries |
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
Past 5 years
USD 6.28
USD 2.11
USD 14.22
USD 18.62
StockViz Staff
January 15, 2025
Any question? Send us an email